As stated earlier, antagonistic approaches have been discussed for GPR183 in inflammatory bowel diseases [59], rheumatoid arthritis [60], and in viral infections [47], and several GPR183 targeting compounds have already been developed [59, 60, 62-64]. Here, GPR183 is linked to inflammatory bowel disease.